New York, March 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Interleukin Inhibitors Global Market Report 2022" - https://www.reportlinker.com/p06241888/?utm_source=GNW
The global interleukin inhibitors market is expected to grow from $26.95 billion in 2021 to $31.73 billion in 2022 at a compound annual growth rate (CAGR) of 17.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $57.87 billion in 2026 at a CAGR of 16.2%.
The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them. These interleukin inhibitors are used for the treatment of autoimmune and inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease
The main types of interleukins inhibitors are IL-17, IL-23, IL-1, IL-5, IL-6, others.Interleukin 17 is a pro-inflammatory cystine knot cytokine family.
In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others and distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market.Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses preventing damage to the host, and maintain normal tissue homeostasis.
There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis.Among these, 20 molecules are in Phase III clinical trials.
These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval.
High costs associated with biological therapy are hampering the interleukin inhibitors market.Biologic treatment that has revolutionized the care of psoriasis patients is expensive than the other treatments.
The total annual cost ranged from $2,077 to US $13,132 for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient.As of 2020, biologics treatment cost was around $10,000 to $30,000 per year.
The higher price of biologics and low healthcare expenditure in developing countries is, therefore, likely to hinder the market growth.
Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative.Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.
For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively.Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs.
This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.
The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06241888/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
